Primenenie sibutramina v kombinatsii s metforminom u zhenshchin reproduktivnogo vozrasta s abdominal'nym tipom ozhireniya

Background. Abdominal obesity is the basic diagnostic criteria for metabolic syndrome. The most important method for preventing metabolic syndrome in its early stages is the effective correction of abdominal obesity. The use of a combination of drugs with different pathogenetic targets and in low doses for the treatment of obesity reduces the risk of side effects for each of them in comparison with their use as monotherapy, but at the maximum dosage. Aim. To compare the efficacy of combined treatment with sibutramine and metformin and metformin as monotherapy after 6 months in women with abdominal obesity. Materials and methods. 20 patients with abdominal obesity received monotherapy with metformin 850 mg/day, 30 patients were prescribed combination therapy (sibutramine 10 mg/day and metformin 850 mg/day). After 6 months, the efficacy and safety of this therapy were compared. Results. The combination of sibutramine and metformin in low doses (n=30) for 6 months more effectively reduces body mass index (p<0.05), waist circumference (p<0.05) than the use of metformin alone (n=20). Conclusions. Administration of sibutramine and metformin combination for 6 months, even in low doses, more effectively reduces body weight (p<0.05), waist circumference (p<0.05) than the use of metformin alone. The combination of sibutramine and metformin in low doses is safe to use. Key words: abdominal obesity, metformin, sibutramine, women of reproductive age. For citation: Batrak G.A., Zhaburina M.V. The use of sibutramine and metformin combination in women of reproductive age with abdominal obesity. Consilium Medicum. 2020; 22 (6): 32-34. DOI: 10.26442/20751753.2020.6.200302

abdominal obesity, metformin, sibutramine, women of reproductive age